Signals
China Just Put a Bispecific ADC Into Esophageal Cancer
China’s NMPA approved iza-bren for recurrent or metastatic esophageal squamous cell carcinoma after platinum chemotherapy and PD-1/PD-L1 therapy. The approval is a regulatory win, but the bigger story is China’s growing ability to move ADC innovation into high-burden cancers.
Down Syndrome Cannot Stay Outside Alzheimer’s Trials
AstraZeneca’s heart drug failure raises a brutal question: how much treatment is too much treatment?
Beans for men, broccoli for women? The real cardiometabolic warning is that risk starts by 22
A Blood Test Will Not Fix Colorectal Screening by Itself
Tau Is Back. Certainty Is Not.
El Salvador Eliminated Trachoma. The Certificate Is Not The Finish Line.
Why some “resistant” hypertension isn’t resistant at all, and what cardiology might be missing
Desmoid Tumours Are Not Benign to the People Living With Them
When Dementia Takes Speech, Trials Must Catch Up
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.